Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 5, 2013, Pages 587-593

  Papadopoulos, Nikolaos ^a   Manolakopoulos, Spilios ^a   Deutsch, Melanie ^a   Mela, Maria ^b   Christidou, Aggeliki ^b   Katoglou, Athina ^a   Tzourmakliotis, Dimitrios ^b   Papatheodoridis, George V ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

Author keywords

barrier; chronic hepatitis C; pegylated interferon

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; DRUG USE; ELASTOGRAPHY; FEMALE; FOLLOW UP; GREECE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; DRUG UTILIZATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; GREECE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84876414494     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835cb5c0     Document Type: Article

References (24)

1. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18 (Suppl 1):1-16.
2. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36 (Suppl):S30-S34. (Pubitemid 35253461)
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347:975-982.
4. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
6. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, Tyndall MW. Low uptake of treatment for hepatitis C virus infection in a large community based-study of inner city residents. J Viral Hepat 2009; 16:352-358.
7. Bini EJ, Brau N, Currie S, Shen H, Anand BS, Hu KQ, et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100:1772-1779. (Pubitemid 41648433)
8. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002; 97:149-155. (Pubitemid 34059779)
9. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292. (Pubitemid 34150758)
10. Kanwal F, Hoang T, Spiegel BMR, Dominitz JA, Gifford A, Goetz M, et al. Predictors of treatment in patients with chronic hepatits C infection-role of patient versus nonpatient factors. Hepatology 2007; 46:1741-1749.
11. European Liver Patients Association (ELPA). Report on hepatitis patient self-help in Europe. Available at: http://www.hepbcppa.org/2010-summit- conference/[Accessed 1 September 2011].
12. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El-Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in Veterans: a national study. Am J Gastroenterol 2011; 106:483-491.
13. McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int 2012; 32 (Suppl 1):151-156.
14. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 (Suppl 5):S313-S320. (Pubitemid 40490217)
15. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33:126-133.
16. Manolakopoulos S, Deutsch MJ, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis GV, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30:1454-1460.
17. Fraenkel L, McGraw S,Wongcharatrawee S, Garcia-Tsao G. What patients consider when making decisions about treatment for hepatitis C? Am J Med 2005; 118:1387-1391. (Pubitemid 41832332)
18. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, et al. Barriers to hepatitis C treatment: a global analysis of physician perceptions. Hepatology 2011; 54:409A-410A.
19. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8:377-383. (Pubitemid 34205892)
20. Shehab TM, Orrego M, Chunduri R, Lok AS. Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol 2003; 98:639-644. (Pubitemid 36348538)
21. Guidelines of the Viral Hepatitis Committee of the Hellenic Center of Prevention and Control of Chronic Diseases. Available at: http://www.keelpno.gr [Accessed 23 September 2011].
22. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
23. EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
24. Beste LA, Straits Troster K, Zickmund S, Larson M, Chapko M, Dominitz JA. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:275-282.